Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 1319082.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
From January 1984 to December 1986, 94 patients with unresectable, locally advanced, non-small cell lung cancer (NSCLC) were treated to assess both the efficacy and the toxicity of a combined modality treatment including radiation therapy (45 Gy/15 fractions/3 weeks) and daily low dose cDDP (6 mg/m2). The overall response rate for the 90 evaluable patients was 54.3% with 16.6% of complete responses. At a minimum follow-up of 4 years, the overall median survival time was 12 months. Provided adequate hydration is ensured, the cDDP regimen chosen as a radiosensitizer can be safely combined with radiation therapy.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Cisplatin
- Lung Neoplasms